Our original approach was to stratify patients into tertiles in line with the publication by Zollars et al., which demonstrated that higher levels of BLyS gene expression were associated with higher levels of clinical and serological SLE activity when patients were divided into low, medium and high BLyS mRNA groups [19]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.